EnterNext félicite IMPLANET pour son introduction en Bourse sur Euronext

Back

Paris, 25 November 2013 – EnterNext, the Euronext subsidiary dedicated to promoting and growing its SME market, today saluted the successful listing of IMPLANET, a medical technology company producing state-of-the-art implants used in orthopaedic surgery. IMPLANT has joined compartment C of Euronext N.V., a wholly owned subsidiary of IntercontinentalExchange Group, Inc. (NYSE: ICE), in Paris.

Founded near Bordeaux in 2007, IMPLANET is recognised for its expertise in producing state-of-the-art orthopaedic implants. Its flagship product, the latest generation JAZZ implant, improves treatment of major deformities and degenerative diseases of the spinal column.

Protected by four international patent families, JAZZ is used in all vertebral fusion procedures, a surgical technique that recreates spinal stability by fusing two adjacent vertebrae and inserts implants to stabilise the resulting structure. Thanks to regulatory approvals already granted, EC marking and FDA approval in the United States, JAZZ’s potential market is estimated at over $2 billion.

IMPLANET (ticker symbol: IMPL) was listed through the admission to trading of 2,955,604 shares making up the company’s equity and 1,959,259 newly shares issued as part of a Global Offering[1], including full exercise of the extension and over-allotmentoptions.

With total demand of around €31.5 million, the issue was oversubscribed 2.3 times, reflecting IMPLANET’s popularity with institutional investors in France and abroad, as well as individual investors. Listing raised a total of €14.1 million.

The admission and issue price of IMPLANET shares was set at €7.20 per share. Market capitalisation on the day of listing came to around €39 million.

“We are delighted to welcome IMPLANET to the very wide selection of biotech and medtech companies listed on Euronext,” said EnterNext Chairman and CEO Eric Forest.“Its successful listing underscores investors’ great interest in SMEs, particularly in this sector. We look forward to helping IMPLANET raise its profile and expand its reach in France and the rest of the world.”

Ludovic Lastennet, CEO of IMPLANET, said: “I am very happy with IMPLANET’s successful listing on Euronext where the number of health stocks has grown steadily and expanded its reach with international investors. I would like to thank all of our historic shareholders, as well as those who have just now joined us to make JAZZ a global success.”

To celebrate listing, Ludovic Lastennet rang the Opening Bell for Euronext’s market. He was accompanied by IMPLANET’s management teams, advisors, and financial and legal affairs partners, along with teams from EnterNext and Euronext.



[1]The Global Offering was made up of a Public Offering in France in the form of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.